Search Results 901-910 of 17113 for monoclonal antibody

1. A Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric or Gastroesophageal Cancer - Mayo Clinic

   Prior allogeneic stem cell transplantation or organ transplantation. 17. History of severe hypersensitivity reactions to other monoclonal antibodies or any

2. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   ... antibody. Eastern Cooperative Oncology Group (ECOG) performance status ... monoclonal antibodies ≤ 14 days prior to registration. Patients who have ...

3. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   ... monoclonal antibodies or Chimeric Antigen Receptor (CAR) T-cell therapy; Patients with a chronic condition requiring the use of systemic corticosteroids at a ...

4. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   Participant has received immune therapy (monoclonal antibody therapy, checkpoint inhibitors) within 4 weeks of lymphodepletion. Participant had major ...

5. Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) - Mayo Clinic

   No history of severe allergic reactions to monoclonal antibodies. Female ... Hepatitis C as indicated by anti-hepatitis C antibody positivity; if a participant is ...

6. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

   ... monoclonal antibodies. Patients must not have received prior treatment with a VEGFR tyrosine kinase inhibitor. Except for Cohort D (MSS mCRC), patients must ...

7. Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary - Mayo Clinic

   ... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks ...

8. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Monoclonal plasma cells in the bone marrow ≥ 10% at ... Subject has known allergies, hypersensitivity, or intolerance to VELCADE, monoclonal antibodies ...

9. Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma - Mayo Clinic

   ... monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled ...

10. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) - Mayo Clinic

    Prior monoclonal antibody within 4 weeks prior to study Day 1 (2 weeks for RS participants) or who has not recovered (i.e. ≤ Grade 1 or at baseline) from ...